Goldman Sachs’s ChemoCentryx, Inc. CCXI Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q4 | – | Sell |
-5,616,301
| Closed | -$290M | – | 6620 |
|
|
2022
Q3 | $290M | Buy |
5,616,301
+5,138,232
| +1,075% | +$212M | 0.07% | 263 |
|
|
2022
Q2 | $11.8M | Buy |
478,069
+92,086
| +24% | +$2.03M | ﹤0.01% | 2343 |
|
|
2022
Q1 | $9.68M | Sell |
385,983
-151,308
| -28% | -$4.25M | ﹤0.01% | 2725 |
|
|
2021
Q4 | $19.6M | Buy |
537,291
+408,850
| +318% | +$14.4M | ﹤0.01% | 2134 |
|
|
2021
Q3 | $2.2M | Sell |
128,441
-109,365
| -46% | -$1.7M | ﹤0.01% | 4116 |
|
|
2021
Q2 | $3.18M | Sell |
237,806
-362,120
| -60% | -$8.92M | ﹤0.01% | 3755 |
|
|
2021
Q1 | $30.7M | Sell |
599,926
-139,621
| -19% | -$8.4M | 0.01% | 1568 |
|
|
2020
Q4 | $45.8M | Buy |
739,547
+267,725
| +57% | +$15.3M | 0.01% | 1188 |
|
|
2020
Q3 | $25.9M | Sell |
471,822
-14,363
| -3% | -$773K | 0.01% | 1535 |
|
|
2020
Q2 | $28M | Buy |
486,185
+266,380
| +121% | +$14.5M | 0.01% | 1412 |
|
|
2020
Q1 | $8.83M | Sell |
219,805
-65,358
| -23% | -$2.78M | ﹤0.01% | 2174 |
|
|
2019
Q4 | $11.3M | Buy |
285,163
+212,067
| +290% | +$3.72M | ﹤0.01% | 2344 |
|
|
2019
Q3 | $496K | Sell |
73,096
-15,798
| -18% | -$119K | ﹤0.01% | 4459 |
|
|
2019
Q2 | $827K | Sell |
88,894
-104,266
| -54% | -$1.21M | ﹤0.01% | 4113 |
|
|
2019
Q1 | $2.68M | Sell |
193,160
-22,652
| -10% | -$259K | ﹤0.01% | 3424 |
|
|
2018
Q4 | $2.35M | Sell |
215,812
-2,561
| -1% | -$27K | ﹤0.01% | 3424 |
|
|
2018
Q3 | $2.76M | Sell |
218,373
-2,074
| -0.9% | -$25K | ﹤0.01% | 3386 |
|
|
2018
Q2 | $2.9M | Buy |
220,447
+18,111
| +9% | +$217K | ﹤0.01% | 3353 |
|
|
2018
Q1 | $2.75M | Sell |
202,336
-64,730
| -24% | -$668K | ﹤0.01% | 3358 |
|
|
2017
Q4 | $1.59M | Buy |
267,066
+46,626
| +21% | +$320K | ﹤0.01% | 3966 |
|
|
2017
Q3 | $1.64M | Buy |
220,440
+147,056
| +200% | +$1.22M | ﹤0.01% | 4151 |
|
|
2017
Q2 | $687K | Sell |
73,384
-5,915
| -7% | -$43.4K | ﹤0.01% | 4804 |
|
|
2017
Q1 | $577K | Buy |
79,299
+20,955
| +36% | +$151K | ﹤0.01% | 4878 |
|
|
2016
Q4 | $432K | Buy |
58,344
+22,810
| +64% | +$164K | ﹤0.01% | 5184 |
|
|
2016
Q3 | $215K | Sell |
35,534
-20,855
| -37% | -$98.5K | ﹤0.01% | 5769 |
|
|
2016
Q2 | $253K | Sell |
56,389
-10,325
| -15% | -$38.7K | ﹤0.01% | 5492 |
|
|
2016
Q1 | $166K | Buy |
66,714
+47,275
| +243% | +$172K | ﹤0.01% | 5766 |
|
|
2015
Q4 | $157K | Buy |
19,439
+2,463
| +15% | +$17.4K | ﹤0.01% | 5879 |
|
|
2015
Q3 | $103K | Buy |
+16,976
| New | +$123K | ﹤0.01% | 6465 |
|
|
2015
Q1 | – | Sell |
-146,834
| Closed | -$1M | – | 7354 |
|
|
2014
Q4 | $1M | Buy |
+146,834
| New | +$776K | ﹤0.01% | 4557 |
|
|
2013
Q4 | – | Sell |
-17,746
| Closed | -$99K | – | 6843 |
|
|
2013
Q3 | $99K | Buy |
+17,746
| New | +$192K | ﹤0.01% | 6160 |
|
Other funds holding CCXI
Goldman Sachs's CCXI Position: Q4 2022 in Review
Goldman Sachs sold out of ChemoCentryx, Inc. (CCXI) in Q4 2022, closing a stake of 5,616,301 shares — an estimated $290M sold.
Goldman Sachs first reported a position in CCXI in Q3 2013 and held it in 31 quarters. The position peaked at $290M in Q3 2022. 1 fund tracked by Wall St. Rank holds CCXI as of Q4 2022.
- Goldman Sachs reported no remaining ChemoCentryx, Inc. position as of Q4 2022 after selling out during the quarter.
- Goldman Sachs sold 5,616,301 ChemoCentryx, Inc. shares in Q4 2022, an estimated $290M.
- Goldman Sachs first reported a position in ChemoCentryx, Inc. in Q3 2013 and held it in 31 quarters.
- Goldman Sachs's ChemoCentryx, Inc. position peaked at $290M in Q3 2022.
- 1 fund tracked by Wall St. Rank held ChemoCentryx, Inc. as of Q4 2022.
Based on Goldman Sachs's 13F filing for Q4 2022, filed 13 Feb 2023.